BCAL Diagnostics Limited (ASX:BDX) Insider Acquires A$50,478.54 in Stock

BCAL Diagnostics Limited (ASX:BDX) insider Jayne Shaw purchased 480,748 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was purchased at an average cost of A$0.11 ($0.07) per share, for a total transaction of A$50,478.54 ($32,566.80).

Jayne Shaw also recently made the following trade(s):

• On Friday, September 13th, Jayne Shaw purchased 125,000 shares of BCAL Diagnostics stock. The stock was acquired at an average cost of A$0.12 ($0.07) per share, for a total transaction of A$14,375.00 ($9,274.19).

BCAL Diagnostics Price Performance

The company has a current ratio of 3.60, a quick ratio of 6.70 and a debt-to-equity ratio of 17.74.

BCAL Diagnostics Company Profile

BCAL Diagnostics Limited, a screening and diagnostic company, engages in developing a non-invasive blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from patient's blood plasma to diagnose the presence of breast cancer cells in a patient's body.